Molecule News and Research

RSS

Rigel Pharmaceuticals reports net loss of $22.3M for first-quarter 2010

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010.

4 May 2010

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended March 31, 2010.

4 May 2010

Approval of personalized therapy for lung cancer in Europe will change way of treatment

The recent approval of Europe's first personalized treatment for lung cancer heralds the arrival of a new era for lung cancer treatment that will demand significant changes to the way cancer specialists and other hospital doctors work, a leading expert said today at the 2nd European Lung Cancer Conference in Geneva, Switzerland.

4 May 2010

NIH awards $3.4M grant for preclinical development of novel Staphylococcus aureus vaccine

GlycoVaxyn AG, a leader in the development of innovative bioconjugate vaccines, and Professor Jean Lee, principal investigator at the Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, announced today that they have received a USD 3.4 million NIH grant to finance preclinical development of a novel Staphylococcus aureus vaccine. S. aureus is a major cause of hospital-based infections.

4 May 2010

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2010.

4 May 2010

Curis completes enrollment in Phase I clinical trial of CUDC-101 HDAC, EGFR and HER2 inhibitor

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has successfully completed enrollment and treatment of the last patient in its Phase I clinical trial of CUDC-101, Curis' first-in-class HDAC, EGFR and HER2 inhibitor.

3 May 2010

Belatacept preserves kidney function in transplant recipients better than cyclosporine, says study

Two-year results from phase III clinical trials show the experimental immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with the standard immunosuppressive drug cyclosporine.

3 May 2010

Protein test to determine response of lung cancer patients to erlotinib

Testing for the presence of specific cancer protein 'fingerprints' in the blood of lung cancer patients may be a useful means of identifying a subgroup whose tumors are more likely to shrink when treated with the drug erlotinib, especially when other testing methods are unavailable, according to new data presented at the 2nd European Lung Cancer Conference in Geneva, Switzerland.

3 May 2010

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

The Scripps Research Institute has been awarded a $1.3 million grant by the National Institutes of Health (NIH) to develop a series of tests at its Florida campus to help explore the potential of a protein that has emerged as a highly attractive target for the treatment of obesity and Type 2 diabetes.

3 May 2010

DSM Biologics partners with Australian Governments to build cGMP mammalian CMO

DSM Biologics is pleased to announce the signing of preliminary agreements to enter a partnership with the Australian Governments (Queensland State Government and the Commonwealth of Australia) to design, build and operate the first major Australia-based mammalian biopharmaceutical manufacturing facility, which will be located in Brisbane.

3 May 2010

New research suggests tumor-secreted exosomes inhibit immune response, enhance tumor metastasis

Current research suggests that tumor-secreted exosomes inhibit the immune response, enhancing tumor metastasis. The related report by Liu et al, "Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells," appears in the May 2010 issue of The American Journal of Pathology.

3 May 2010

Scientists discover two body clock genes that may help find treatments for seasonal affective disorder

Scientists have discovered two "body clock" genes that reveal how seasonal changes in hormones are controlled and could ultimately help find treatments for seasonal affective disorder.

3 May 2010

Mutations in several genes associated with developmental brain disorder: Study

Although there is no known cause of autism, studies have shown that mutations in several genes are associated with the developmental brain disorder. New research has uncovered two additional genes that may be involved with autism.

3 May 2010

Approval of Provenge marks beginning of new era in cancer treatment: Dana-Farber Cancer Institute

Today's announcement that the U.S. Food and Drug Administration has approved Provengeâ, a new form of therapy for some prostate cancer patients, marks the beginning of an era in which patients' own immune systems become part of the standard therapeutic arsenal against cancer, say Dana-Farber Cancer Institute investigators who led a study of the treatment's effectiveness in patients.

30 Apr 2010

Researchers identify key protein that regulates innate immune system

A team of researchers led by Baylor College of Medicine has identified a protein called NLRC5, a member of the NOD-like protein family, that is involved in inhibition of protein complexes key to critical pathways of innate immunity called NF-κB and type I interferon signaling. A report on their work appears in the current issue of the journal Cell.

30 Apr 2010

Canadian researchers identify new therapeutic target for lung cancer

Lung cancer patients whose tumors over-express a cell surface molecule called CXCR4 do significantly worse than those who do not, Canadian researchers have found. Their work, reported at the 2nd European Lung Cancer Conference in Geneva, highlights the exciting possibility that the molecule could soon become a new target for personalized cancer therapy.

30 Apr 2010

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the first quarter of 2010.

30 Apr 2010

Nanotechnology for study of individual molecule interaction in live cells

A University of Alberta-led research team has taken a major step forward in understanding how T cells are activated in the course of an immune response by combining nanotechnology and cell biology. T cells are the all important trigger that starts the human body's response to infection.

29 Apr 2010

Ago2 protein helps generate microRNAs: CSHL researchers

MicroRNAs are small bits of RNA within cells that wield enormous power. They influence virtually every biological process by controlling the "expression" of genes. Helping them in exerting this control is a unique class of proteins called Argonautes.

29 Apr 2010

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Lycera Corporation, a biopharmaceutical company pioneering an innovative approach to developing novel oral medicines to treat autoimmune diseases, today announced that the company has made important progress, triggering a second tranche of $11 million in its Series A financing. Proceeds from the second tranche will be used to continue to advance Lycera's discovery and development efforts and further support the growth of the company.

29 Apr 2010

Molecule News and Research

Rigel Pharmaceuticals reports net loss of $22.3M for first-quarter 2010

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Approval of personalized therapy for lung cancer in Europe will change way of treatment

NIH awards $3.4M grant for preclinical development of novel Staphylococcus aureus vaccine

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Curis completes enrollment in Phase I clinical trial of CUDC-101 HDAC, EGFR and HER2 inhibitor

Belatacept preserves kidney function in transplant recipients better than cyclosporine, says study

Protein test to determine response of lung cancer patients to erlotinib

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

DSM Biologics partners with Australian Governments to build cGMP mammalian CMO

New research suggests tumor-secreted exosomes inhibit immune response, enhance tumor metastasis

Scientists discover two body clock genes that may help find treatments for seasonal affective disorder

Mutations in several genes associated with developmental brain disorder: Study

Approval of Provenge marks beginning of new era in cancer treatment: Dana-Farber Cancer Institute

Researchers identify key protein that regulates innate immune system

Canadian researchers identify new therapeutic target for lung cancer

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Nanotechnology for study of individual molecule interaction in live cells

Ago2 protein helps generate microRNAs: CSHL researchers

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News